A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Geoffrey Y. Ku(Memorial Sloan Kettering Cancer Center), Samuel J. Klempner(Broad Institute), Jeremy D. Kratz(University of Wisconsin–Madison), Farshid Dayyani(University of California, Irvine), Zhenning Wang(First Hospital of China Medical University), Peter Sabbatini(Jiangsu T-mab BioPharma (China)), Jordan Berlin(Dana-Farber Cancer Institute), Juyeun Jeon(ABL Bio (South Korea)), Hongming Pan(Sir Run Run Shaw Hospital), Claire Xu(Jiangsu T-mab BioPharma (China)), Christoph M. Ahlers(Bristol-Myers Squibb (Germany)), Reva Schneider(Mary Crowley Cancer Research Center), Eugenia Girda(Rutgers, The State University of New Jersey), Ting Deng(Tianjin Medical University Cancer Institute and Hospital), Lin Shen(Peking University), Funan Liu(First Hospital of China Medical University), Kristen Spencer(Rutgers Cancer Institute), John D. Powderly(Carolina BioOncology Institute), Jin-Young Park(ABL Bio (South Korea)), Tianshu Liu(Sun Yat-sen University), Xinjun Liang(Hubei Provincial Center for Disease Control and Prevention), Xuejun Liu(Shanxi Medical University), Yangmi Lim(ABL Bio (South Korea)), Laura Feller(Horizon Oncology Center), Yuan Meng(Jiangsu T-mab BioPharma (China)), Yanhong Deng(Sun Yat-sen University), Jou-Ku Chung(Jiangsu T-mab BioPharma (China)), Sunnie S. Kim(University of Colorado Cancer Center)
Cited by 16
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k